据报道,盘前市场上Viking Therapeutics, Inc.(VKTX)股票大涨20.41%,引发投资者广泛关注。
导致VKTX股价暴涨的主要原因,是该公司的竞争对手诺和诺德公司旗下新型肥胖症药物CagriSema在后期临床试验中的减重效果未达预期。诺和诺德公布,该药物仅能帮助超重患者减轻22.7%的体重,低于预期的25%。
作为肥胖症药物的开发商,VKTX等公司的竞争力因此提高,前景获得提振。投资者对这些公司未来的增长潜力更有信心,因而推升了VKTX等相关股票的股价。但诺和诺德在美国的股票盘前暴跌22.4%,与其主要竞争对手礼来公司的Wegovy药物的成功形成鲜明对比。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.